# AML Multi-Omics Integration: Comprehensive Analysis Roadmap

**Project:** Beat AML Multi-Omics Integration Study

**Generated:** 2025-10-02

**Version:** 1.0

---

## Table of Contents

1. [Executive Summary](#executive-summary)
2. [Cohort Overview](#cohort-overview)
3. [TIER 1: Core Multi-Omics Analyses](#tier-1-core-multi-omics-analyses-highest-priority)
4. [TIER 2: Clinical Integration Analyses](#tier-2-clinical-integration-analyses-high-priority)
5. [TIER 3: Advanced Integrative Analyses](#tier-3-advanced-integrative-analyses-exploratory)
6. [Implementation Timeline](#implementation-timeline)
7. [Feasibility Summary](#feasibility-summary)
8. [Resource Requirements](#resource-requirements)
9. [Success Metrics](#success-metrics)

---

## Executive Summary

This roadmap outlines **16 comprehensive analyses** for the Beat AML multi-omics integration project, organized into 3 priority tiers:

- **TIER 1 (Highest Priority):** 4 core multi-omics analyses
- **TIER 2 (High Priority):** 6 clinical integration analyses
- **TIER 3 (Exploratory):** 6 advanced integrative analyses

### Overall Feasibility

**15/16 analyses are fully feasible** with the available Beat AML cohort.

All analyses have been power-calculated and are supported by robust sample sizes across multiple data type combinations.

### Key Statistics

- **Mean Statistical Power:** 0.81
- **Gold Standard Cohort (all 4 data types):** n = 478
- **Expression + Drug:** n = 494
- **Survival Data:** n = 942 (565 events, 60%)

### Estimated Timeline

| Tier | Sequential | Parallel |
|------|------------|----------|
| **Tier 1** | 8-12 weeks | 6-8 weeks |
| **Tier 2** | 7-10 weeks | 5-7 weeks |
| **Tier 3** | 11-16 weeks | 8-10 weeks |
| **TOTAL** | **26-38 weeks** | **19-25 weeks** |

With parallelization and adequate resources, the project can be completed in **~5-6 months**.

---

## Cohort Overview

### Available Sample Sizes by Data Type Combination

| Data Type Combination | Sample Size | Key Analyses |
|----------------------|-------------|--------------|
| Expression only | n = 707 | Molecular subtyping |
| Mutations only | n = 871 | Mutation landscape |
| Drug Response only | n = 603 | Drug screening |
| Clinical only | n = 934 | Demographics |
| Expression + Mutations | n = 615 | Mutation-expression integration |
| Expression + Drug | n = 494 | Drug prediction |
| Mutations + Drug | n = 583 | Mutation-drug associations |
| Expression + Clinical | n = 671 | Clinical-molecular correlation |
| **Gold Standard (all 4)** | **n = 478** | **Multi-omics integration** |
| Survival data | n = 942 (565 events) | Prognostic analyses |

---

## TIER 1: Core Multi-Omics Analyses (HIGHEST PRIORITY)

These foundational analyses establish the molecular landscape and provide essential insights for all downstream analyses.

### Analysis 1.1: Molecular Subtyping via Expression

**Status:** ✓ **FEASIBLE** | **Power:** 0.90 | **Timeline:** 2-3 weeks

**Goal:** Identify transcriptomic subtypes in AML

**Methods:** Consensus clustering, hierarchical clustering, k-means

**Sample Size:**
- Required: n ≥ 100
- Available: n = 707

**Data Requirements:** Expression data

**Justification:** n=707 with min cluster size ~141

**Scripts Location:** `02_Scripts/04_Molecular_Subtyping/`

**Deliverables:**
- Cluster assignments for each sample
- Subtype-specific gene signatures (DEGs per cluster)
- Heatmaps showing cluster-specific expression patterns
- PCA/t-SNE plots with cluster annotations
- Biological interpretation via pathway analysis (GSEA, Reactome)
- Clinical correlation of subtypes (survival, age, mutations)

---

### Analysis 1.2: Comprehensive Mutation Landscape

**Status:** ✓ **FEASIBLE** | **Power:** 0.90 | **Timeline:** 1-2 weeks

**Goal:** Characterize mutational profile of AML cohort

**Methods:** Mutation frequency, co-occurrence analysis, mutual exclusivity

**Sample Size:**
- Required: n ≥ 200
- Available: n = 871

**Data Requirements:** Mutation data

**Justification:** n=871, can detect mutations ≥5.7%

**Scripts Location:** `02_Scripts/04_Molecular_Subtyping/`

**Deliverables:**
- OncoPrint visualization of top driver mutations
- Mutation frequency bar plots (overall and by subtype)
- Co-occurrence and mutual exclusivity matrix
- Mutational signature analysis (if WGS data available)
- Driver vs passenger mutation classification
- Comparison with TCGA-AML and other public datasets

---

### Analysis 1.3: Mutation-Expression Integration

**Status:** ✓ **FEASIBLE** | **Power:** 0.90 | **Timeline:** 2-3 weeks

**Goal:** Understand how mutations affect gene expression

**Methods:** Differential expression analysis stratified by mutation status

**Sample Size:**
- Required: n ≥ 50
- Available: n = 615

**Data Requirements:** Expression + Mutation data

**Justification:** n=615, 10/10 mutations powered

**Scripts Location:** `02_Scripts/06_Integration/`

**Deliverables:**
- DEG lists for each mutation (FDR < 0.05, |log2FC| > 1)
- Volcano plots for key mutations
- Pathway enrichment analysis (KEGG, Reactome, GO)
- Gene Set Enrichment Analysis (GSEA) using MSigDB
- Heatmaps of top differentially expressed genes
- Mutation-specific expression signatures

**Key Comparisons:** DNMT3A; NPM1; NRAS; TET2; IDH2

---

### Analysis 1.4: Drug Response Prediction from Multi-Omics

**Status:** ✓ **FEASIBLE** | **Power:** 0.85 | **Timeline:** 3-4 weeks

**Goal:** Predict drug sensitivity using expression + mutations

**Methods:** Machine learning (Random Forest, Elastic Net, XGBoost)

**Sample Size:**
- Required: n ≥ 150
- Available: n = 478

**Data Requirements:** Expression + Mutations + Drug Response

**Justification:** n=478, Train/Val/Test: 286/95/97

**Scripts Location:** `02_Scripts/05_Drug_Response/`

**Deliverables:**
- Predictive models for top 20 drugs (Random Forest, Elastic Net, XGBoost)
- Feature importance rankings (genes + mutations)
- Cross-validation performance metrics (R², RMSE, MAE)
- Independent test set validation
- Biomarker identification (top predictive features)
- Drug-specific response signatures

---

## TIER 2: Clinical Integration Analyses (HIGH PRIORITY)

These analyses integrate molecular features with clinical outcomes to identify prognostic biomarkers and validate clinical utility.

### Analysis 2.1: Survival Analysis with Multi-Omics Features

**Status:** ✓ **FEASIBLE** | **Power:** 0.90 | **Timeline:** 2-3 weeks

**Goal:** Identify prognostic biomarkers from multi-omics data

**Methods:** Cox regression, Kaplan-Meier curves, risk stratification

**Sample Size:**
- Required: n ≥ 100
- Available: n = 942

**Data Requirements:** Survival + Clinical + Expression + Mutations

**Justification:** n=942, 565 events (60.0%)

**Scripts Location:** `02_Scripts/07_Survival_Analysis/`

**Deliverables:**
- Univariate Cox regression for all features
- Multivariate Cox model with top features
- Kaplan-Meier curves for risk groups
- Risk score calculation and validation
- Time-dependent ROC curves
- Prognostic signature identification

---

### Analysis 2.2: Mutation-Drug Response Associations

**Status:** ✓ **FEASIBLE** | **Power:** 0.80 | **Timeline:** 2-3 weeks

**Goal:** Identify mutation-specific drug sensitivities/resistances

**Methods:** Stratified AUC comparison, effect size calculation

**Sample Size:**
- Required: n ≥ 40
- Available: n = 583

**Data Requirements:** Mutations + Drug Response

**Justification:** n=583, key pairs have ≥20 per group

**Key Associations:**
- FLT3 vs FLT3 inhibitors (Sorafenib, Gilteritinib)
- IDH1 vs IDH inhibitors (Ivosidenib)
- IDH2 vs IDH inhibitors (Enasidenib)
- DNMT3A vs Hypomethylating agents (Azacitidine)
- NPM1 vs Venetoclax

**Scripts Location:** `02_Scripts/05_Drug_Response/`

**Deliverables:**
- Mutation-stratified drug sensitivity plots
- Effect size calculations (Cohen's d) for each pair
- Statistical testing (t-test, Mann-Whitney U)
- Volcano plot of mutation-drug associations
- Precision medicine implications
- Actionable biomarkers for drug selection

---

### Analysis 2.3: Integrated Network Analysis

**Status:** ✓ **FEASIBLE** | **Power:** 0.80 | **Timeline:** 3-4 weeks

**Goal:** Construct multi-omics interaction networks

**Methods:** Correlation networks, pathway analysis, module detection

**Sample Size:**
- Required: n ≥ 100
- Available: n = 478

**Data Requirements:** Expression + Mutations + Drug Response

**Justification:** n=478 for integrated networks

**Scripts Location:** `02_Scripts/06_Integration/`

**Deliverables:**
- Gene-gene correlation networks
- Mutation-expression regulatory networks
- Drug-target-expression networks
- Module detection (WGCNA or similar)
- Hub gene identification
- Network-based biomarker discovery

---

### Analysis 2.4: Survival Analysis by Molecular Features

**Status:** ✓ **FEASIBLE** | **Power:** 0.85 | **Timeline:** 2 weeks

**Goal:** Identify prognostic molecular features in AML

**Methods:** Kaplan-Meier curves, Cox proportional hazards regression

**Sample Size:**
- Required: n ≥ 100
- Available: n = 942

**Data Requirements:** Survival + Expression + Mutations + Clinical

**Justification:** n=942 total, 565 events (60.0%), 11/11 stratifications powered

**Stratifications:**
- Molecular Subtypes
- Mutation: FLT3
- Mutation: NPM1
- Mutation: TP53
- Mutation: DNMT3A
- ... and 6 more

**Scripts Location:** `02_Scripts/07_Survival_Analysis/`

**Deliverables:**
- Kaplan-Meier curves for all stratifications
- Hazard ratios with 95% confidence intervals
- Forest plots summarizing HR across features
- Univariate Cox regression results
- Multivariate Cox models (adjusted for clinical covariates)
- Log-rank test p-values
- Median survival times per group

---

### Analysis 2.5: Clinical-Molecular Correlation

**Status:** ✓ **FEASIBLE** | **Power:** 0.72 | **Timeline:** 1 week

**Goal:** Associate molecular features with clinical variables

**Methods:** Chi-square test, t-test, ANOVA, Fisher exact test

**Sample Size:**
- Required: n ≥ 100
- Available: n = 615

**Data Requirements:** Clinical + Expression + Mutations

**Justification:** n=615, 4/5 associations powered

**Associations to Test:**
- Mutations vs Age
- Mutations vs Gender
- Molecular Features vs De Novo/Secondary
- Gene Expression vs Blast %

**Scripts Location:** `02_Scripts/07_Survival_Analysis/`

**Deliverables:**
- Association tables with test statistics and p-values
- Visualization plots (boxplots, bar charts, heatmaps)
- Effect size calculations (Cohen's d, Cramer's V, odds ratios)
- Multiple testing correction (FDR, Bonferroni)
- Summary report of significant associations

---

### Analysis 2.6: Integrated Prognostic Model

**Status:** ✓ **FEASIBLE** | **Power:** 0.85 | **Timeline:** 2-3 weeks

**Goal:** Build comprehensive prognostic model combining clinical and molecular features

**Methods:** Multivariate Cox proportional hazards regression

**Sample Size:**
- Required: n ≥ 100
- Available: n = 615

**Data Requirements:** Survival + Clinical + Expression + Mutations

**Justification:** n=615, 368 events, 26.3 events/predictor

**Feature Categories:**
- Clinical (5)
- Mutations (7)
- Expression (2)

**Scripts Location:** `02_Scripts/07_Survival_Analysis/`

**Deliverables:**
- Risk stratification model (low/intermediate/high risk)
- Nomogram for individual risk prediction
- C-index (concordance index) for model discrimination
- Calibration plots (predicted vs observed survival)
- Internal validation (bootstrap or cross-validation)
- Risk score formula and coefficients
- Comparison with existing prognostic models (e.g., ELN risk)

---

## TIER 3: Advanced Integrative Analyses (EXPLORATORY)

These exploratory analyses provide advanced insights and develop translational tools for precision medicine.

### Analysis 3.1: Subtype-Specific Drug Sensitivities

**Status:** ✓ **FEASIBLE** | **Power:** 0.80 | **Timeline:** 2 weeks

**Goal:** Identify drugs with differential sensitivity across subtypes

**Methods:** ANOVA, pairwise comparisons, effect size calculation

**Sample Size:**
- Required: n ≥ 60
- Available: n = 494

**Data Requirements:** Expression + Drug Response (requires Analysis 1.1)

**Justification:** n=494, ~165 per subtype

**Dependencies:** Requires Analysis 1.1 completion

**Scripts Location:** `02_Scripts/05_Drug_Response/`

**Deliverables:**
- Subtype-stratified drug sensitivity plots
- ANOVA results for all drugs
- Subtype-specific drug rankings
- Precision medicine recommendations
- Heatmap of subtype-drug associations

---

### Analysis 3.2: Clinical-Molecular Correlations

**Status:** ✓ **FEASIBLE** | **Power:** 0.70 | **Timeline:** 1-2 weeks

**Goal:** Associate clinical features with molecular profiles

**Methods:** Correlation analysis, stratified comparisons

**Sample Size:**
- Required: n ≥ 100
- Available: n = 478

**Data Requirements:** Clinical + Expression + Mutations

**Justification:** n=478 with complete clinical data

**Scripts Location:** `02_Scripts/06_Integration/`

**Deliverables:**
- Age vs expression/mutation associations
- Sex-stratified molecular profiles
- Prior treatment vs molecular features
- WBC count vs expression signatures
- Clinical subgroup comparisons (ELN risk, FAB classification)

---

### Analysis 3.3: Drug Combination Synergy Analysis

**Status:** ⚠ **LIMITED** | **Power:** 0.60 | **Timeline:** 2-3 weeks

**Goal:** Identify synergistic drug combinations

**Methods:** Correlation analysis, synergy scoring (if combination data available)

**Sample Size:**
- Required: n ≥ 100
- Available: n = 603

**Data Requirements:** Drug Response (multiple drugs per sample)

**Justification:** n=603, but single-drug screening limits analysis

⚠ **Caveat:** Limited by single-drug screening design

**Scripts Location:** `02_Scripts/05_Drug_Response/`

**Deliverables:**
- Drug-drug correlation matrix
- Predicted synergistic pairs (correlation-based)
- Pathway-based combination hypotheses
- Literature-validated combinations

---

### Analysis 3.4: Multi-Omics Network Analysis

**Status:** ✓ **FEASIBLE** | **Power:** 0.80 | **Timeline:** 4-6 weeks

**Goal:** Integrate all 4 data types into unified biological network

**Methods:** Network analysis, pathway integration, graph-based methods

**Sample Size:**
- Required: n ≥ 50
- Available: n = 478

**Data Requirements:** Complete quad-omics (Expression + Mutations + Drug + Clinical)

**Justification:** n=478 quad-omics, 4/4 approaches feasible

**Network Approaches:**
- Co-expression Networks
- Mutation-Expression Networks
- Drug-Target Networks
- Multi-Layer Networks

**Scripts Location:** `02_Scripts/06_Integration/`

**Deliverables:**
- Gene-gene co-expression networks (WGCNA modules)
- Mutation-expression regulatory networks
- Drug-target-pathway integration maps
- Multi-layer network visualizations (Cytoscape)
- Hub gene/node identification
- Network-based biomarker discovery
- Pathway enrichment analysis
- Network communities/modules linked to clinical outcomes

---

### Analysis 3.5: Drug Mechanism Discovery

**Status:** ✓ **FEASIBLE** | **Power:** 0.81 | **Timeline:** 3-4 weeks

**Goal:** Understand molecular changes associated with drug response

**Methods:** Correlation analysis, differential expression, pathway enrichment

**Sample Size:**
- Required: n ≥ 100
- Available: n = 494

**Data Requirements:** Expression + Drug Response

**Justification:** n=494 expr+drug, 4/4 components feasible

**Analysis Components:**
- Gene-Drug Correlation
- Pathway Associations
- Drug Response Signatures
- Mutation-Drug Mechanisms

**Scripts Location:** `02_Scripts/05_Drug_Response/`

**Deliverables:**
- Gene-drug correlation matrix (top 1000 genes × all drugs)
- Pathway enrichment results for each drug class
- Drug response signatures (sensitive vs resistant)
- Volcano plots for key drugs
- Drug mechanism hypotheses based on molecular profiles
- Target validation (literature comparison)
- Drug repurposing opportunities

---

### Analysis 3.6: Personalized Treatment Recommendation Framework

**Status:** ✓ **FEASIBLE** | **Power:** 0.81 | **Timeline:** 4-6 weeks

**Goal:** Develop framework for patient-specific drug selection based on molecular profile

**Methods:** Integrate molecular profile → drug prediction → clinical recommendation

**Sample Size:**
- Required: n ≥ 100
- Available: n = 478

**Data Requirements:** Complete quad-omics (for training); Expression + Mutations minimum (for deployment)

**Justification:** n=478 for training, 4/4 components feasible

**Framework Components:**
- Profile Integration
- Drug Prediction Models
- Decision Support
- Clinical Validation

**Scripts Location:** `02_Scripts/08_Personalized_Medicine/`

**Deliverables:**
- Patient molecular profile dashboard (web interface or R Shiny)
- Drug ranking algorithm with confidence scores
- Validation report (accuracy, concordance)
- Clinical decision support tool
- User manual and deployment guide
- Case studies (example patients with recommendations)
- Comparison with standard-of-care treatment selection

---

## Implementation Timeline

### Recommended Execution Order

#### Phase 1: Foundation (Weeks 1-8)
**Objective:** Establish molecular landscape

- Analysis 1.1: Molecular Subtyping (parallel)
- Analysis 1.2: Mutation Landscape (parallel)
- Analysis 1.3: Mutation-Expression Integration (after 1.1, 1.2)

#### Phase 2: Prediction & Clinical Integration (Weeks 9-16)
**Objective:** Build predictive models and clinical correlations

- Analysis 1.4: Drug Response Prediction (after Phase 1)
- Analysis 2.1: Survival by Molecular Features (parallel)
- Analysis 2.4: Survival Analysis (after 1.1)
- Analysis 2.5: Clinical-Molecular Correlation (parallel)

#### Phase 3: Advanced Integration (Weeks 17-24)
**Objective:** Advanced analyses and prognostic modeling

- Analysis 2.2: Mutation-Drug Associations (parallel)
- Analysis 2.3: Network Analysis (parallel)
- Analysis 2.6: Integrated Prognostic Model (after 2.4, 2.5)
- Analysis 3.1: Subtype-Specific Drug Sensitivities (after 1.1)

#### Phase 4: Exploratory & Translational (Weeks 17-30)
**Objective:** Advanced discoveries and clinical tools

- Analysis 3.2: Clinical-Molecular Correlations (parallel)
- Analysis 3.3: Drug Combination Synergy (exploratory)
- Analysis 3.4: Multi-Omics Network Analysis (parallel)
- Analysis 3.5: Drug Mechanism Discovery (parallel)
- Analysis 3.6: Personalized Treatment Framework (final)

## Feasibility Summary

### All Analyses

| Analysis ID | Analysis Name | Sample Size | Power | Feasibility |
|-------------|---------------|-------------|-------|-------------|
| 1.1 | Molecular Subtyping via Expression | 707 | 0.90 | ✓ YES |
| 1.2 | Comprehensive Mutation Landscape | 871 | 0.90 | ✓ YES |
| 1.3 | Mutation-Expression Integration | 615 | 0.90 | ✓ YES |
| 1.4 | Drug Response Prediction from Multi-Omics | 478 | 0.85 | ✓ YES |
| 2.1 | Survival Analysis with Multi-Omics Features | 942 | 0.90 | ✓ YES |
| 2.2 | Mutation-Drug Response Associations | 583 | 0.80 | ✓ YES |
| 2.3 | Integrated Network Analysis | 478 | 0.80 | ✓ YES |
| 2.4 | Survival Analysis by Molecular Features | 942 | 0.85 | ✓ YES |
| 2.5 | Clinical-Molecular Correlation | 615 | 0.72 | ✓ YES |
| 2.6 | Integrated Prognostic Model | 615 | 0.85 | ✓ YES |
| 3.1 | Subtype-Specific Drug Sensitivities | 494 | 0.80 | ✓ YES |
| 3.2 | Clinical-Molecular Correlations | 478 | 0.70 | ✓ YES |
| 3.3 | Drug Combination Synergy Analysis | 603 | 0.60 | ⚠ LIMITED |
| 3.4 | Multi-Omics Network Analysis | 478 | 0.80 | ✓ YES |
| 3.5 | Drug Mechanism Discovery | 494 | 0.81 | ✓ YES |
| 3.6 | Personalized Treatment Recommendation Framework | 478 | 0.81 | ✓ YES |

### Summary by Tier

**TIER 1:** 4/4 feasible (mean power: 0.89)
**TIER 2:** 6/6 feasible (mean power: 0.82)
**TIER 3:** 5/6 feasible (mean power: 0.75)

**OVERALL:** 15/16 analyses are fully feasible

## Resource Requirements

### Personnel

- **Bioinformatician (Lead):** 1 FTE for entire project
- **Computational Biologist:** 1 FTE for advanced analyses (Tier 2-3)
- **Statistician:** 0.5 FTE for power analyses and validation
- **Clinical Collaborator:** 0.25 FTE for clinical interpretation

### Computational Resources

- **High-performance computing:** Required for network analysis and ML models
- **Storage:** ~500 GB for processed data and results
- **RAM:** ≥64 GB recommended for expression matrix operations

### Software & Tools

- **R packages:** DESeq2, limma, WGCNA, survival, caret
- **Python libraries:** scikit-learn, pandas, seaborn, lifelines
- **Pathway databases:** MSigDB, KEGG, Reactome
- **Visualization:** Cytoscape, R Shiny (for personalized framework)

## Success Metrics

### Tier 1 Completion Criteria

- [ ] Molecular subtypes identified and validated
- [ ] Comprehensive mutation landscape characterized
- [ ] Mutation-expression associations identified (FDR < 0.05)
- [ ] Drug prediction models achieve R² > 0.3

### Tier 2 Completion Criteria

- [ ] Prognostic molecular features identified (p < 0.05)
- [ ] Clinical-molecular associations validated
- [ ] Integrated prognostic model C-index > 0.7
- [ ] Mutation-drug associations confirmed

### Tier 3 Completion Criteria

- [ ] Multi-omics networks constructed and validated
- [ ] Drug mechanisms elucidated
- [ ] Personalized treatment framework deployed

### Publication Targets

- **High-impact journals:** Nature Communications, Cell Reports, Blood
- **Minimum publications:** 3-5 primary research articles
- **Data release:** GEO/dbGaP deposition for reproducibility

---

## Document Information

**Version:** 1.0

**Last Updated:** 2025-10-02

**Contact:** AML Multi-Omics Project Team

**Related Documents:**
- Statistical Power Analysis Report
- Clinical Integration Analyses Specification
- Analysis Cohort Definitions
